Skip to main content
Home
  • Clinical Outcome Assessments
    Clinical Outcome Assessments

    What are Clinical Outcome Assessments (COAs)? What do they measure?

    Learn more about COAs
    hero_1.jpeg
    The most trusted distributor of COAs

    700+ exclusive COA distributions on behalf of their copyright owners

    hero_2.jpeg
    PROQOLID™: the largest COA database

    7,000+ COAs described in details and accessible in this unique database

  • Services
    Services

    Mapi Research Trust provides turnkey solutions for your Clinical Outcome Assessments (COAs) strategies - including COA databases, targeted literature reviews, licensing.

    Read More
    COA Databases Patient-Centered Endpoint Intelligence COA Licensing Translation and Linguistic Validation eCOA Licensing COA Repository
    hero_3.jpeg
    About ePROVIDE™

    Online access to all our services and COA databases

    hero_2_2.jpeg
    What are eBooklets?

    Find out more about this step-by-step guidance for valid digitization of COAs

  • Author Collaboration
    Author Collaboration

    Our team is dedicated to assisting authors in the daily management of their questionnaires and all derivatives, including translations and electronic versions

    Read More
    COA distribution COA copyright and protection Promotion of COAs and developers Testimonials
    hero_3_1.jpeg
    Catalog of COAs distributed by Mapi Research Trust

    800+ exclusive distributions of COAs, accessible in ePROVIDE

  • Resources
    Resources

    ACCESS all our resources on COAs and eCOA: webinars, publications, blogs. SUBSCRIBE to receive email updates.

    Read More
    Blog Publications Useful links Webinar recordings Whitepapers
    Whitepaper-Digitizing-COAs.jpg
    New whitepaper

    Digitizing COAs: A streamlined approach to approval

    hero_4_2.jpeg
    New whitepaper

    COAs and copyright: How to mitigate risks of infringement and misuse in clinical research and practice

  • News & Events
    News & Events

    Stay informed with our latest news and check all our upcoming events. SUBSCRIBE to get email updates.

    Read More
    hero_5_1.jpeg
    News
    Hero_5_2.jpeg
    Conferences
    Hero_5_3.jpeg
    Webinars
  • About us
    About us

    Mapi Research Trust is a non-profit organization dedicated to improving patients’ quality of life by facilitating access to Clinical Outcome Assessments(COAs).

    Read More
    hero_6_1.jpeg
    Team

    A global team of multi-disciplinary experts

    hero_6_2.jpeg
    Experience

    Collecting & Processing Patient Centered Outcomes information for more than two decades

  • Contact
  1. Home
  2. Resources
  3. Mapi Publications
  4. Pulmonary–Respiratory

Pulmonary–Respiratory

Articles

  • 2017. Pavel ME et al. – Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

  • 2017. Miles C et al. – Barriers and facilitators of effective self-management in asthma: Systematic review and thematic synthesis of patient and healthcare professional views

  • 2017. Cooper WA et al. – Intra- and inter-observer reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer (NSCLC)

  • 2016. Linneberg A et al. – Burden of allergic respiratory disease: A systematic review

  • 2016. Morélot-Panzini C et al. – Real-life assessment of the multidimensional nature of dyspnoea in COPD patients

  • 2016. Medic G et al. – Efficacy and safety of aclidinium/formoterol versus tiotropium in COPD: Results of an indirect treatment comparison

  • 2016. de La Loge C et al. – Relationship between FEV1 and patient-reported outcomes changes: Results of a meta-analysis of randomized trials in stable COPD

  • 2016. Chen YJ et al. – Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists

  • 2015. Ismaila AS et al. – Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: A systematic review and network meta-analysis

  • 2015. Huisman EL et al. – Comparative efficacy of combination bronchodilatator thrapies in COPD: A network meta-analysis

  • 2014. Karabis A et al. – Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: An analysis over 5 years

  • 2013. Cope S et al. – Comparative efficacy of long-acting bronchodilators for COPD – A network meta-analysis

  • 2013. Chouaid C et al. – Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real world setting

  • 2013. Lapillonne A et al. – Development of a questionnaire to assess the impact on parents of their infant’s bronchiolitis hospitalization

  • 2013. Karabis A et al. – Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: A systematic review and network meta-analysis

  • 2012. Lapillonne A et al. – Impact on parents of bronchiolitis hospitalization of full-term, preterm and congenital heart disease infants

  • 2012. Littlewood KJ et al. – A network meta-analysis of the efficacy of inhaled antibiotics for chronic pseudomonas infections in cystic fibrosis

  • 2012. Verduyn SC et al. – Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non-small cell lung cancer patients in The Netherlands

  • 2012. Cope S et al. – Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

  • 2012. Cope S et al. – Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: A patient level mixed treatment comparison

  • 2012. Cope S et al. – Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol/budesonide or salmeterol/fluticasone for COPD: A network meta-analysis

  • 2011. Aguilaniu B et al. – Disability related to COPD tool (DIRECT): Towards an assessment of COPD-related disability in routine practice

  • 2011. Cope S et al. – Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – A network meta-analysis

  • 2009. Perez T et al. – Validity, reliability, and responsiveness of a new short Visual Simplified Respiratory Questionnaire (VSRQ) for health-related quality of life assessment in chronic obstructive pulmonary disease

  • 2003. Stǻhl E et al. – Health-related quality of life in asthma studies. Can we combine data from different countries?

Posters & Presentations

  • 2017. ISPOR European Congress – Impact of different baseline definitions on the incidence of relevant outcomes associated with cancer following an advanced non-small cell lung cancer (NSCLC) diagnosis
  • 2016. IASLC World Conference on Lung Cancer – Have we shifted the therapeutic innovation frontier? A US assessment of advanced non–small cell lung cancer (advNSCLC)
  • 2016. ISPOR European Congress – Baseline Characteristics and Survival of Patients Diagnosed with Advanced NSCLC in Sweden Between 2006 and 2013, Matched (1:4) to a Comparison Cohort from the General Population
  • 2016. ISOQOL Annual Conference – Standardised Translation of the Bronchiectasis Health Questionnaire (BHQ) into Eleven Languages
  • 2016. ERS International Congress – Comparative Efficacy of Umeclidinium/Vilanterol versus LABA/LAMA Therapies in COPD: A Network Meta-Analysis
  • 2016. ERS International Congress – Translation of the Bronchiectasis Health Questionnaire Using Validated Methods
  • 2016. ISPOR Annual International Meeting – Value of Innovation in Oncology Treatments for Patients in Sweden with Advanced or Metastatic Non-Small Cell Lung Cancer (advNSCLC)
  • 2015. ISPOR European Congress – Psychometric Validation of the Multidimensional Dyspnea Profile (MDP) Questionnaire
  • 2015. ISPOR Annual International Meeting – Usability Testing of the Web-Based Versions of the Standardised Asthma Quality of Life Questionnaire for 12 years and Older (AQLQ(S)+12) and the Asthma Control Questionnaire (ACQ-6)
  • 2015. ISPOR Annual International Meeting – A Review of Health-Related Quality of Life (HRQL) Claims in Labels of Asthma Products – Can We Consider the Asthma Quality of Life Questionnaire (AQLQ) as a Potentially Acceptable Measure for Qualification?
  • 2014. ISPOR European Congress – Comparative efficacy of umeclidinium bromide versus other long-acting anticholinergic monotherapies as treatments for COPD patients
  • 2014. ISPOR European Congress – Systematic Review of Observational Studies and RCTs of Omalizumab in Severe Persistent Allergic Asthma and Meta-Analysis Feasibility Assessment
  • 2014. ISOQOL Annual Conference – Development of E-Versions of the Asthma Quality of Life Questionnaire (Standardised) [AQLQ(S)] in Twenty (20) Languages for Use on Handheld Devices
  • 2014. ERS Annual Meeting – Comparative assessment of umelidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
  • 2013. ISPOR European Congress – Evaluating Whether Inconsistencies Are Present in a Mixed Treatment Comparison of Trough Forced Expiratory Volume in 1 Second at 12 Weeks
  • 2013. ISPOR European Congress – Network Meta-Analysis with Fractional Polynomials for Repeated Trough FEV1 Measures in COPD: Aclidinium Bromide 400 μg Bid Versus Tiotropium 18 μg QD
  • 2013. ISPOR European Congress – Development of an Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) for 6-10 Year Old Patients in 11 Languages
  • 2013. ISPOR European Congress – Efficacy of Inhaled Antibiotics in CF Patients with Chronic P. Aeruginosa Infection: A Network Meta-Analysis
  • 2013. ISPOR European Congress – Addressing Heterogeneity in Baseline Risk of COPD Exacerbations Using Meta-Regression
  • 2013. ISPOR European Congress – Patient-Reported Outcome (PRO) Claims in Products Approved for Chronic Obstructive Pulmonary Diseases (COPD) in Europe and in the USA
  • 2013. ISPOR European Congress – Economic Evaluation of Ceftobiprole Compared to a Combination of Linezolid with Ceftazidime in the Management of Hospitalised Pneumonia in Scotland
  • 2013. ISPOR European Congress – Assessing Non-Inferiority of Aclidinium Bromide 400 μg Bid Versus Tiotropium 18 μg and 5 μg QD in Patients with Chronic Obstructive Pulmonary Disease (COPD) by Means of a Network Meta-Analysis
  • 2013. ICPE Meeting – Prevalence and Incidence of Idiopathic Pulmonary Fibrosis in UK Healthcare Databases, GPRD and THIN; the Need for an IPF Registry
  • 2013. ISPOR Annual International Meeting – Economic Evaluation of Aclidinium Bromide in the Management of Moderate-to-Severe COPD
  • 2013. ISPOR Annual International Meeting – Patient-Reported Outcomes (PROs) Claims in Products Indicated for Treatment of Non-Small Cell Lung Carcinoma and Approved in Europe and in the United States
  • 2013. ISPOR Annual International Meeting – Development of the 6-10 Year Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA) in Spanish for Guatemala and Peru
  • 2012. ISPOR European Congress – Dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD. A network meta-analysis of FEV1
  • 2012. ISPOR European Congress – Comparative efficacy of Aclidinium Bromide 400 µg bid versus Tiotropium 18 µg and 5 µg QD as maintenance bronchodilatator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD): A network meta-analysis
  • 2012. ISPOR European Congress – Efficacy of Ceftaroline Fosamil and Other Intravenous Antibiotics in the Treatment of Community-Acquired Pneumonia (CAP): A Network Meta-Analysis (NMA)
  • 2012. CHEST – The association between rescue medication use and future exacerbations in COPD – A retrospective analysis of randomized controlled trials
  • 2012. ISPOR Asia-Pasific Conference – The Copyright of Translations of PRO Instruments: The Case of Instruments Used in Lung Diseases
  • 2012. ISPOR Asia Pacific Conference – Clinical COPD Questionnaire (CCQ): Is There a Need to Develop a Specific English Version for the Philippines and India
  • 2012. ISPOR Annual International Meeting – Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results from a Phase III Clinical Trial
  • 2012. ISPOR Annual International Meeting – Acceptability of the Self-Administered Computerized (SAC) Versions of the Baseline/Transition Dyspnea Indexes (BDI/ TDI) for Patients with COPD from Seven Countries
  • 2012. ATS Conference – Comparative efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + uticasone for the treatment of chronic obstructive pulmonary disease
  • 2011. ISPOR European Congress – Importance of Collaboration with Developers in the Clarification of Concepts: A Case Study with the University of California, San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)
  • 2011. ISPOR European Congress – Testing of a Conceptual Model of Asthma in Adolescents
  • 2011. ISPOR European Congress – Quality of Life in Small Cell Lung Cancer: Results of an Open-Label Phase III Clinical Trial
  • 2011. ISPOR Annual International Meeting – Overview of Primary Endpoints, Progression Free-Survival (PFS) and Overall Survival (OS) for Non-Small Cell Lung Cancer (NSCLC): Their Value in Treatment Decisions and Patient Care
  • 2010. ISPOR European Congress – Testing the Usability and Language of ePRO Translations during Linguistic Validation: Cognitive Debriefing on eDevice Vs. Print Out of Screenshots
  • 2010. ISPOR European Congress – Mixed Treatment Comparison of Bevacizumab-Based Therapies Relative to Doublet-Chemotherapy Combinations to Estimate the Relative Efficacy in Progression Free Survival for Treatment of First-Line Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
  • 2009. ISOQOL Annual Conference – Is it Necessary to Develop English Versions of the Asthma Quality of Life Questionnaire (AQLQ)?
  • 2009. ISPOR European Congress – Item Selection and Scoring Definition of a Disease-Specific Instrument to Assess the Handicap in Chronic Obstructive Pulmonary Disease (COPD) Patients, For Use in Clinical Routine Practice
  • 2009. ISPOR Annual International Meeting – Development of a Specific Questionnaire Assessing the Impact on Parents of an Infant’s Bronchiolitis Hospitalization
  • 2008. ISPOR European Congress – Use of an Electronic Diary in 55 Countries: What are the Challenges?
  • 2008. ISPOR European Congress – Symptoms and Impact of Symptoms as Reported by Asthma Patients
  • 2008. ISPOR European Congress – How Congruent Are Patients and Clinician Models of Asthma Control? – Preliminary Finding from a Qualitative Study
  • 2008. ISPOR Annual International Meeting – Treatment Satisfaction Questionnaires in Asthma and Other Chronic Diseases
  • 2006. ISPOR European Congress – Measuring the impact of COPD on Patients’ Lives in an International Study
  • 2005. ISPOR European Congress – Patient-Reported Impact of Cough and Sputum in Chronic (Obstructive) Bronchitis – Simultaneous Development of the Self-Administered CASA-Q
  • 2005. ISPOR European Congress – Impact of Dyspnoea on Daily Activities in COPD Patients – Development and Testing of a New Questionnaire for Clinical Practice and Clinical Trials.
Site Branding
    ICON plc
  • Contact
  • About Us
For Clients
  • Services
  • Resources
  • ePROVIDE™
News & Events
  • News
  • Conferences
  • Webinars
Socials
  • Linkedin

Legal Footer

  • © 2025 Mapi Research Trust
  • Disclaimer
  • Privacy
  • Site Cookies
How can we help?
  • All
Popular search terms:
  • COVID-19
  • Site & Patient Recruitment
  • Oncology
  • Medical Device
  • Real World Evidence
  • Decentralised & hybrid clinical trials
  • Digital Disruption